Kiniksa Pharmaceuticals International, plc
KNSA
Rang în acțiuni
#2871
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Preț acțiune
$83.13
Capitalizare de piață
$6.49B
Schimbare (1 zi)
4.59%
Schimbare (1 an)
113.21%
Țară
GB
Tranzacționează Kiniksa Pharmaceuticals International, plc (KNSA)
Categorie
Healthcare
Istoricul spliturilor pentru Kiniksa Pharmaceuticals International, plc (KNSA)
Acțiunea Kiniksa Pharmaceuticals International, plc (simbol: KNSA) a trecut printr-un total de 0 splituri.
Cel mai recent split a avut loc pe Oct 20, 2026.
O acțiune KNSA cumpărată înainte de Oct 20, 2026 este echivalentă astăzi cu 0 acțiuni KNSA.
Cel mai recent split a avut loc pe Oct 20, 2026.
O acțiune KNSA cumpărată înainte de Oct 20, 2026 este echivalentă astăzi cu 0 acțiuni KNSA.
Listă splituri acțiuni
| An | Split | Multiplu | Multiplu cumulativ |
|---|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | |||
Splituri pentru companii similare sau competitori
| Companie | Număr total de splituri | Multiplu cumulativ | Țara |
|---|---|---|---|
| 0 | - |
US
|
|
| 0 | - |
SE
|
|
| 0 | - |
FR
|
|
| 0 | - |
IT
|
|
| 0 | - |
US
|
